Vertex Pharmaceuticals Incorporated
IT ˙ BIT ˙ US92532F1003
366,30 € ↓ -1,30 (-0,35%)
2026-06-03
AKTIENPREIS
SecurityIT:1VRTX / Vertex Pharmaceuticals Incorporated
InstitutionCommerce Bank
Latest Disclosed Ownership7,535 shares
Latest Disclosed Value $ 3,364,678
Commerce Bank reports 7.66% increase in ownership of 1VRTX / Vertex Pharmaceuticals Incorporated

On May 11, 2026 - Commerce Bank filed a 13F-HR form disclosing ownership of 7,535 shares of Vertex Pharmaceuticals Incorporated (IT:1VRTX) valued at $2,860,286 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 6,999 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 7.66% during the quarter. The current value of the position is $2,760,070 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,535 536 7.66 3,365 6.02 0.0069
2026-02-13 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,999 67 0.97 3,173 16.91 0.0175
2025-11-12 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,932 -558 -7.45 2,715 -18.60 0.0151
2025-08-07 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 7,490 -853 -10.22 3,335 -17.56 0.0197
2025-05-08 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,343 -295 -3.42 4,045 16.27 0.0258
2025-02-13 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,638 1,195 16.06 3,479 0.49 0.0214
2024-11-08 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 7,443 775 11.62 3,462 10.75 0.0212
2024-08-12 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,668 8 0.12 3,125 12.29 0.0202
2024-05-03 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,660 -364 -5.18 2,784 -2.59 0.0184
2024-02-09 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,024 89 1.28 2,858 18.50 0.0203
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,935 -116 -1.65 2,412 -2.82 0.0190
2023-08-08 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 7,051 289 4.27 2,481 16.48 0.0186
2023-05-04 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,762 -451 -6.25 2,131 2.31 0.0167
2023-02-10 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,213 472 7.00 2,083 6.66 0.0169
2022-11-04 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,741 72 1.08 1,952 3.89 0.0170
2022-08-12 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,669 -98 -1.45 1,879 6.40 0.0153
2022-05-09 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,767 1,378 25.57 1,766 49.16 0.0121
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,389 464 9.42 1,184 32.59 0.0077
2021-11-09 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,925 -294 -5.63 893 -15.11 0.0063
2021-08-09 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,219 -319 -5.76 1,052 -11.60 0.0075
2021-05-05 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,538 363 7.01 1,190 -2.78 0.0091
2021-02-09 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,175 -314 -5.72 1,224 -18.02 0.0099
2020-11-06 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,489 547 11.07 1,493 4.04 0.0135
2020-08-07 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 4,942 -821 -14.25 1,435 4.67 0.0140
2020-05-08 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,763 1,506 35.38 1,371 47.10 0.0166
2020-02-14 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 4,257 531 14.25 932 47.70 0.0089
2019-11-12 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,726 147 4.11 631 -3.96 0.0065
2019-08-07 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,579 104 2.99 657 2.82 0.0074
2019-05-08 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,475 93 2.75 639 13.90 0.0076
2019-02-11 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,382 964 39.87 561 20.39 0.0071
2018-11-02 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,418 40 1.68 466 15.35 0.0055
2018-08-08 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,378 366 18.19 404 23.17 0.0051
2018-05-03 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,012 75 3.87 328 13.10 0.0043
2018-02-12 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,937 235 13.81 290 11.97 0.0038
2017-11-07 2017-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 1,702 100 6.24 259 25.73 0.0035
2017-11-07 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,602 206
2017-08-08 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,602 1,602 206 0.0029
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.